Leica Microsystems has received an FDA 510(k) approval for the Leica FL800, an intra-operative video angiography device for the viewing of blood flow in the cerebral vascular area using Akorn ICG. This is the only FDA (U.S. Food and Drug Administration) approval for video angiography in the cerebral vascular area using ICG (IndoCyanine Green) as a fluorescent agent.
Surgeons with experience in vascular fluorescence have commented that the goal of ICG fluorescence lies in the quick and easy visualization of blood flow, which subsequently enables them to determine the permeability of vessels and effects of their surgery while they are operating through the Leica surgical microscope. Surgeons at a recent Congress of Neurosurgery in Chicago commented that real time vascular fluorescence is the biggest advance in intra-operative vascular neurosurgery in years.
The Leica FL800 fluorescence system is designed as a combination of an excitation light system, an ICG fluorescent agent, and a near infra-red camera to achieve the result. The FDA 510(k) approval for the Leica FL800 was limited to the Akorn ICG, Leica surgical microscopes, and to the cerebral vascular area. Leica Microsystems may consider additional application extensions to its FDA approval in the future.
The Leica FL800 vascular fluorescence procedure is quite simple for the surgeon to perform. The ICG agent is injected intravenously and the surgeon presses one button. The special NIR camera than picks up the fluorescent signal and displays it to the surgeon in real time. In addition the Leica FL800 records the imaging as a special loop so the surgeon can repeat the image later in surgery. This procedure can be repeated six times in a single surgery so the surgeon can track the effects of his surgical procedure on blood flow in the brain.
Each person who wants to market Class I, II and some III devices intended for human use in the U.S. must submit a 510(k) to FDA at least 90 days before marketing unless the device is exempt from 510(k) requirements. A 510(k) is a premarketing submission made to FDA (U.S. Food and Drug Administration) to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent (SE) to a legally marketed device that is not subject to premarket approval. In case of approval the device can be legally marketed in the US.
Leica Microsystems is a leading global designer and producer of innovative, high-tech, precision optical systems for the analysis of microstructures. It is one of the market leaders in each of its business areas: Microscopy, Confocal Laser Scanning Microscopy, Imaging Systems, Specimen Preparation and Medical Equipment. The company manufactures a broad range of products for numerous applications requiring microscopic imaging, measurement, and analysis. It also offers system solutions for life science including biotechnology and medicine, research and development of raw materials, and industrial quality assurance. The company is represented in over 100 countries with 8 manufacturing facilities in 6 countries, sales and service organizations in 19 countries and an international network of dealers. With its workforce of about 3,200 employees it made turnover of US$ 597m in 2005. The international management is headquartered in Wetzlar, Germany.
Visualizing gene expression with MRI
23.12.2016 | California Institute of Technology
Illuminating cancer: Researchers invent a pH threshold sensor to improve cancer surgery
21.12.2016 | UT Southwestern Medical Center
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences